|Bid||3.1000 x 1100|
|Ask||3.2900 x 800|
|Day's Range||3.0900 - 3.2850|
|52 Week Range||0.6200 - 4.0300|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.70|
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to three new employees with a grant date of February 24, 2021, as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on February 24, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).
If you're like me, you're an eternal optimist when it comes to the march of scientific progress and its ability to improve human life. The stocks that I'll discuss today are micro-cap stocks, which means that they have market capitalizations between $50 million and $300 million. Think of them as early stage public companies that don't have much consistent revenue yet.
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual meeting format.